Cost-Minimization Analysis of Lanthanum Carbonate Versus Sevelamer Hydrochloride in US Patients With End-stage Renal Disease.

MLA

Keith, Michael S., et al. “Cost-Minimization Analysis of Lanthanum Carbonate Versus Sevelamer Hydrochloride in US Patients With End-Stage Renal Disease.” Clinical Therapeutics, vol. 36, no. 9, Sept. 2014, pp. 1276–86. EBSCOhost, https://doi.org/10.1016/j.clinthera.2014.06.036.

APA

Keith, M. S., Wilson, R. J., Preston, P., & Brian Copley, J. (2014). Cost-Minimization Analysis of Lanthanum Carbonate Versus Sevelamer Hydrochloride in US Patients With End-stage Renal Disease. Clinical Therapeutics, 36(9), 1276–1286. https://doi.org/10.1016/j.clinthera.2014.06.036

Chicago

Keith, Michael S., Rosamund J. Wilson, Peter Preston, and J. Brian Copley. 2014. “Cost-Minimization Analysis of Lanthanum Carbonate Versus Sevelamer Hydrochloride in US Patients With End-Stage Renal Disease.” Clinical Therapeutics 36 (9): 1276–86. doi:10.1016/j.clinthera.2014.06.036.